** Shares of drug developer BioAge Labs crater 67.6% to $6.52 in extended trading
** Co discontinues mid-stage trial of its experimental obesity drug after high levels of certain liver enzymes observed in some patients
** BioAge's experimental drug, azelaprag, mimics activity of the exerkine apelin, a peptide released in response to exercise due to muscle contraction
** Co was studying azelaprag as a monotherapy and in combination with Eli Lilly's tirzepatide
** BioAge has stopped dosing all patients and plans to further analyze data from people who have been enrolled
** As of last close, stock down ~10% since its market debut in September
(Reporting by Juveria Tabassum in Bengaluru)
((Juveria.Tabassum@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。